$2.23
0.45% today
Nasdaq, Feb 28, 05:06 pm CET
ISIN
US4380831077
Symbol
QTTB
Sector
Industry

Homology Medicines, Inc. Stock price

$2.24
-1.00 30.86% 1M
-35.58 94.08% 6M
-1.20 34.88% YTD
-14.23 86.40% 1Y
-60.58 96.43% 3Y
-276.94 99.20% 5Y
-333.64 99.33% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.10 4.27%
ISIN
US4380831077
Symbol
QTTB
Sector
Industry

Key metrics

Market capitalization $27.28m
Enterprise Value $-42.38m
P/E (TTM) P/E ratio negative
P/B ratio (TTM) P/B ratio 1.49
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-60.99m
Cash position $89.08m
EPS (TTM) EPS $-14.21
P/E forward negative
Short interest 0.04%
Show more

Is Homology Medicines, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Homology Medicines, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Homology Medicines, Inc. forecast:

1x Buy
20%
4x Hold
80%

Analyst Opinions

5 Analysts have issued a Homology Medicines, Inc. forecast:

Buy
20%
Hold
80%

Financial data from Homology Medicines, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 0.37 0.37
81% 81%
-
-0.37 -0.37
1,025% 1,025%
-
- Selling and Administrative Expenses 21 21
24% 24%
-
- Research and Development Expense 39 39
55% 55%
-
-61 -61
47% 47%
-
- Depreciation and Amortization 0.37 0.37
81% 81%
-
EBIT (Operating Income) EBIT -61 -61
48% 48%
-
Net Profit -50 -50
62% 62%
-

In millions USD.

Don't miss a Thing! We will send you all news about Homology Medicines, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Homology Medicines, Inc. Stock News

Neutral
PRNewsWire
about 3 hours ago
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata (AA) -- WALTHAM, Mass. , Feb. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune ...
Neutral
PRNewsWire
2 days ago
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced that management will participate in two upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference Date: Wednesday, March 5, 2025 Presentation Time: 11:50...

Company Profile

Homology Medicines, Inc. operates as a technology platform to design and develop treatments to address rare diseases at the genetic level. It develops genetic medicines by translating proprietary, next generation gene editing and gene therapy technologies into novel treatments for patients with rare diseases. The company was founded by Saswati Chatterjee in 2015 and is headquartered in Bedford, MA.

Head office United States
CEO Jodie Morrison
Employees 7
Founded 2015
Website www.q32bio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today